These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 28532857)

  • 21. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study.
    Susumu N; Sagae S; Udagawa Y; Niwa K; Kuramoto H; Satoh S; Kudo R;
    Gynecol Oncol; 2008 Jan; 108(1):226-33. PubMed ID: 17996926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
    Van Gool IC; Stelloo E; Nout RA; Nijman HW; Edmondson RJ; Church DN; MacKay HJ; Leary A; Powell ME; Mileshkin L; Creutzberg CL; Smit VT; Bosse T
    Mod Pathol; 2016 Feb; 29(2):174-81. PubMed ID: 26743472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
    Zhao XD; Zhang Q; Zhang Y
    Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing the effect of guideline introduction on clinical practice and outcome in patients with endometrial cancer in Japan: a project of the Japan Society of Gynecologic Oncology (JSGO) guideline evaluation committee.
    Shigeta S; Nagase S; Mikami M; Ikeda M; Shida M; Sakaguchi I; Ushioda N; Takahashi F; Yamagami W; Yaegashi N; Udagawa Y; Katabuchi H
    J Gynecol Oncol; 2017 Nov; 28(6):e76. PubMed ID: 29027394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel.
    Su D; Smith SM; Preti M; Schwartz P; Rutherford TJ; Menato G; Danese S; Ma S; Yu H; Katsaros D
    Cancer; 2009 Jun; 115(11):2453-63. PubMed ID: 19322891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer.
    Werner HM; Trovik J; Halle MK; Wik E; Akslen LA; Birkeland E; Bredholt T; Tangen IL; Krakstad C; Salvesen HB
    PLoS One; 2014; 9(2):e90141. PubMed ID: 24587245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer.
    Nagao S; Nishikawa T; Hanaoka T; Kurosaki A; Iwasa N; Hasegawa K; Fujiwara K
    Jpn J Clin Oncol; 2014 Nov; 44(11):1040-4. PubMed ID: 25183770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
    Grushko TA; Filiaci VL; Mundt AJ; Ridderstråle K; Olopade OI; Fleming GF;
    Gynecol Oncol; 2008 Jan; 108(1):3-9. PubMed ID: 17945336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Jeske YW; Ali S; Byron SA; Gao F; Mannel RS; Ghebre RG; DiSilvestro PA; Lele SB; Pearl ML; Schmidt AP; Lankes HA; Ramirez NC; Rasty G; Powell M; Goodfellow PJ; Pollock PM
    Gynecol Oncol; 2017 May; 145(2):366-373. PubMed ID: 28314589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retrospective analysis of second-line chemotherapy outcomes with paclitaxel or docetaxel in correlation with STMN1 polymorphism in advanced non-small cell lung cancer patients.
    Powrózek T; Mlak R; Krawczyk P; Bartoń S; Biernacka B; Małecka-Massalska T; Milanowski J
    Clin Transl Oncol; 2016 Jan; 18(1):33-9. PubMed ID: 26148901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Significance of prognostic evaluation of International Federation of Gynecology and Obstetrics 2009 staging system on stage I endometrioid adenocarcinoma].
    Wang ZQ; Zhang Y; Wang JL; Shen DH; Mu T; Zhao X; Yao YY; Bai Y; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Jan; 47(1):33-9. PubMed ID: 22455691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.
    Alvarez Secord A; Havrilesky LJ; Bae-Jump V; Chin J; Calingaert B; Bland A; Rutledge TL; Berchuck A; Clarke-Pearson DL; Gehrig PA
    Gynecol Oncol; 2007 Nov; 107(2):285-91. PubMed ID: 17688923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Whole abdominal radiotherapy versus combination chemotherapy with doxorubicin and cisplatin in advanced endometrial carcinoma (phase III): Gynecologic Oncology Group Study No. 122.
    Randall ME; Spirtos NM; Dvoretsky P
    J Natl Cancer Inst Monogr; 1995; (19):13-5. PubMed ID: 7577198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adult Comorbidity Evaluation 27 score as a predictor of survival in endometrial cancer patients.
    Binder PS; Peipert JF; Kallogjeri D; Brooks RA; Massad LS; Mutch DG; Powell MA; Thaker PH; McCourt CK
    Am J Obstet Gynecol; 2016 Dec; 215(6):766.e1-766.e9. PubMed ID: 27457116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
    Wang Y; Yu M; Yang JX; Cao DY; Zhang Y; Shen K; You Y
    Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):816-822. PubMed ID: 30585019
    [No Abstract]   [Full Text] [Related]  

  • 37. Prolonged survival among women with BRCA germline mutations and advanced endometrial cancer: a case series.
    Kwon JS; Lenehan J; Carey M; Ainsworth P
    Int J Gynecol Cancer; 2008; 18(3):546-9. PubMed ID: 17645508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stathmin and phospho-stathmin protein signature is associated with survival outcomes of breast cancer patients.
    Kuang XY; Chen L; Zhang ZJ; Liu YR; Zheng YZ; Ling H; Qiao F; Li S; Hu X; Shao ZM
    Oncotarget; 2015 Sep; 6(26):22227-38. PubMed ID: 26087399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
    Krill L; Deng W; Eskander R; Mutch D; Zweizig S; Hoang B; Ioffe O; Randall L; Lankes H; Miller DS; Birrer M
    Gynecol Oncol; 2020 Feb; 156(2):423-429. PubMed ID: 31843273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study.
    Modesitt SC; Tian C; Kryscio R; Thigpen JT; Randall ME; Gallion HH; Fleming GF;
    Gynecol Oncol; 2007 Apr; 105(1):59-65. PubMed ID: 17150247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.